New Graves Disease Findings from Medical University of Bialystok Described (Effect of methimazole treatment on Th1, Th17, and Th22 lymphocytes in pediatric Graves' disease patients).

A study conducted at the Medical University of Bialystok in Poland focused on the impact of methimazole treatment on Th1, Th17, and Th22 lymphocytes in pediatric Graves' disease patients. The research highlighted the significant role of these effector T lymphocytes in the pathogenesis of Graves' disease and their potential predictive value for therapy outcomes. The study found that low Th17/Th22 ratio values could serve as prognostic factors for normalizing TSH levels in response to methimazole treatment. For more information, the full article is available in Frontiers in Immunology, with contact information for the researchers provided. [Extracted from the article]